BioPharmSignal logoBioPharmSignal

Biotech News

Assembly Biosciences Announces Upcoming Investor Conference Presentations

Assembly Biosciences (ASMB)Assembly BiosciencesConference / presentation

SOUTH SAN FRANCISCO, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver diseases, today announced senior management will participate in fireside chats at two upcoming

Related news

ASMBAssembly Biosciences2026-04-09 12:00 EST

Assembly Biosciences Highlights Presentations on Positive Phase 1b Data for ABI-5366 and ABI-1179 in Recurrent Genital Herpes at ESCMID Global 2026

ASMBAssembly Biosciences2026-05-11 12:00 EST

Assembly Biosciences to Present at the BofA Securities 2026 Global Health Care Conference

OGENOragenics2026-05-19 12:45 EST

Oragenics to Present at Sidoti’s Micro-Cap Virtual Investor Conference May 20-21

ENTAEnanta Pharmaceuticals2026-05-28 11:00 EST

Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

ANTXAN2 Therapeutics2026-05-21 11:00 EST

AN2 Therapeutics to Present at 2026 Jefferies Global Healthcare Conference

ENTAEnanta Pharmaceuticals2026-05-04 11:00 EST

Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus and STAT6 Inhibitor Programs at the American Thoracic Society International Conference 2026

MBRXMoleculin Biotech, Inc.2026-03-17 13:05 EST

Moleculin to Present at 38th Annual ROTH Conference

ANTXAN2 Therapeutics2026-02-17 12:00 EST

AN2 Therapeutics to Participate in Fireside Chat at Leerink Global Healthcare Conference

AVIRAtea2026-01-06 12:00 EST

Atea Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference

AVIRAtea2025-11-19 12:00 EST

Atea Pharmaceuticals to Present at the 8th Annual Evercore Healthcare Conference

View all latest news

Assembly Biosciences

Antiviral Small Molecules Assembly Biosciences develops oral small-molecule therapies for serious viral diseases. Its portfolio targets viral replication mechanisms with the goal of improving suppression or enabling finite treatment. Recurrent Genital Herpes ABI-5366 and ABI-1179 are helicase-primase inhibitors that have completed Phase...

Recent company news

ASMBAssembly Biosciences2026-05-28 20:05 EST

Assembly Biosciences Announces Upcoming Investor Conference Presentations

ASMBAssembly Biosciences2026-05-26 20:05 EST

Assembly Biosciences Announces the Closing of its Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

ASMBAssembly Biosciences2026-05-22 11:05 EST

Assembly Biosciences Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants

ASMBAssembly Biosciences2026-05-22 11:00 EST

Assembly Biosciences Announces Expansion of ABI-6250 Clinical Development Into Cholestatic Liver Diseases

ASMBAssembly Biosciences2026-05-13 06:00 EST

Assembly Biosciences to Present Topline Phase 1a Data on Hepatitis Delta Virus Entry Inhibitor ABI-6250 at the EASL Congress 2026

Stock data

Close
26.45 USD
Market cap
485.32M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States